Target intelligence / Profile preview

Solute carrier family 39 member 14 (SLC39A14)

Target
SLC39A14
Molecular classification
Transporter, Metal ion transporter, Solute carrier family, Zrt- and Irt-like protein (ZIP) family
01

Overview

Solute carrier family 39 member 14 (SLC39A14; also known as ZIP14) is a **metal ion transporter** in the ZIP family, primarily facilitating the uptake of zinc, manganese, iron, and cadmium into cells[2][3]. SLC39A14 is widely expressed, including in liver, pancreas, muscle, adipose tissue, and the brain[2][3][7]. It helps maintain systemic and cellular metal ion homeostasis and plays essential roles in **regulating glucose metabolism, insulin secretion, immune signaling, and systemic growth**[1][2][4][5]. ZIP14 is upregulated during inflammation and is involved in the body's acute-phase response, modulating signaling pathways such as GPCR-mediated cAMP generation, NF-κB, and STAT3[4][5][6]. Germline mutations in SLC39A14 can cause **hereditary manganese accumulation and neurotoxicity**, while its dysregulation influences susceptibility to metabolic inflammation, obesity, and cachexia[3][5][7]. As a transporter, SLC39A14 is a potential therapeutic target in disorders of metal ion metabolism and related systemic diseases.

Other names
ZIP14Metal cation symporter ZIP14KIAA0062LZT-Hs4NET34ZIP-14LIV-1 subfamily of ZIP zinc transporter 4Zrt- and Irt-like protein 14zinc transporter 14HCINHMNDYT2cig19
02

Mechanism of action

Not applicable for approved drugs; mechanisms studied involve alteration of metal transport to modulate intracellular zinc, iron, or manganese levels that impact signaling pathways (e.g., GPCR-cAMP-CREB pathway, inhibition of phosphodiesterases, modulation of insulin signaling)[4].

03

Biological functions

Metal ion transport (zinc, manganese, iron, cadmium)Regulation of glucose homeostasisModulation of inflammatory signalingControl of G-protein-coupled receptor–mediated signalingRegulation of systemic growth and energy metabolismModulation of insulin secretionAdipocyte differentiation and metabolism
04

Disease associations

Hepatic and systemic iron/zinc/manganese overload disorders (e.g., hereditary manganese-induced neurotoxicity)Metabolic syndromeDiabetes (regulation of insulin and glucose homeostasis)Obesity (impacts adipose tissue inflammation and function)Inflammatory diseases (modulates response to endotoxemia)Muscle wasting/cachexiaNeurodegenerative disease (due to manganese accumulation)
05

Safety considerations

Toxic metal overload (especially manganese neurotoxicity)Alterations in glucose and insulin homeostasis, with potential for hypoglycemia or hyperinsulinemiaIncreased risk of inflammation and impaired immunity during transporter dysfunctionPotential for impaired differentiation and increased adiposity or muscle wasting
06

Interacting drugs

No clinically approved drugs directly targeting SLC39A14 are available as of the latest literature. However, research agents (siRNAs, metal chelators) and altered metal ion supplementation/chelation regimens modulate its function in studies[1][2][5].
07

Biomarkers

Elevated blood and tissue manganese for SLC39A14 deficiency (notably in inherited manganese metabolism disorders)[3].Zinc and iron homeostasis markers (serum zinc, hepcidin, ferritin)[2].

Beyond the preview

Go deeper on Solute carrier family 39 member 14 (SLC39A14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 39 member 14 (SLC39A14).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call